Vall d'Hebron presents positive results from two studies in transfusion-dependent thalassaemia and severe bone marrow aplasia at the EBMT Annual Meeting on haematopoietic stem cell transplantation.

The study, in which Vall d'Hebron participates, helps to understand the variability among patients with retinitis pigmentosa.

La iniciativa "Sin Piedad" explica la història d'en David, un nen que s'està tractant d'un càncer pediàtric, un exemple d'actitud lluitadora davant la malaltia.

The money will allow research into paediatric nervous system tumours and childhood sarcomas to continue, with the aim of improving children's chances of survival and reducing the side effects of treatment.

The association makes the fifth annual donation of 52,390€ that will finance a project to study new therapies for this childhood tumor.

The BEACON clinical trial, in which Vall d'Hebron participates, has observed that adding Bevacizumab to treatment with different chemotherapy drugs reduces tumor size in a greater number of patients.

The study, which is part of the European RECOMB project, is currently recruiting volunteers.

This clinical trial is part of the European project RBDCOV, led by HIPRA in which Vall d'Hebron participates, whose recruitment is still open.

The meeting has been the meeting point of the EpSSG group dedicated to research to improve the treatment of childhood and adolescent soft tissue sarcomas.

‘RBDCOV Talks' brings vaccine clinical research closer to the general audience through a podcast series with 10 scientists, clinicians, specialists and community advocates who are partners in the project.

The funds will enable the recruitment and retention of young talent, as well as the development of a new epigenetic drug

The initiative, coordinated by Dr. Pablo Velasco and Dr. Jose Luis Fuster, aims to bring innovation closer to patients and promote research projects in this disease.

The project aims to test the HIPRA vaccine against COVID-19 in children (including adolescents) and immunocompromised people.

The meeting, in which Dr. Pere Soler participated, showed the results of the first year with the description of new genetic defects associated with severe forms of COVID-19 and novelties in the detection of autoantibodies against interferons.

The platform offers health workers the latest information on infectious and tropical diseases and also serves as a training tool.

The ClinPrior algorithm achieved a positive diagnosis rate of 70% in two minority diseases of neurodegenerative origin, which represents double the number of cases that are diagnosed with current tools.

This initiative has several collaborative projects with the aim of increasing knowledge about rare blood diseases and improving patient care.

The multicenter phase 1 trial has been conducted in patients aged 2 to 21 years with solid tumors unresponsive to standard treatments or in relapse.

The presentations include the one given by Dr. María Pérez Torres, who received the award for the best oral communication for a project on the use of mesenchymal cells to reduce complications after hematopoietic progenitor transplantation.

The donation will go towards two studies aimed at improving the quality of life of paediatric liver transplant patients.

On International Clinical Trials Day, we highlight the increase in VHIR clinical research over the last year.

Dr. Lucas Moreno is the first author of the international work that presents a series of considerations for early phase studies with the aim of accelerating the arrival of new therapies to patients with childhood cancer.

A study, in which Vall d'Hebron has participated, has analysed all the interventions of this type carried out between 2006 and 2020.

Els actes amb motiu del Dia de les Malalties Minoritàries fan possible que pacients amb malalties diferents es trobin i s’ajudin